IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies. We are applying these capabilities across multiple classes of precision medicine: direct targeting of oncogenic pathways – and synthetic lethality – which represents an emerging class of precision medicine targets. This diversified approach enables our objective to deliver the right medicine to the right patient to drive a more robust clinical response.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
June 16, 2020 at 8:00 AM EDT
June 2, 2020 at 11:00 AM EDT
January 15, 2020 at 5:00 PM PST